Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share (WVE)

Historical Holders from Q4 2015 to Q4 2025

Type / Class
Equity / Common Stock, $0.00001 par value per share
Symbol
WVE on Nasdaq
Shares outstanding
189,947,836
Price per share
$17.00
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
143,683,496
Total reported value
$1,051,664,882
% of total 13F portfolios
0%
Share change
+4,795,142
Value change
+$37,209,381
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
187
Price from insider filings
$16.70
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share (WVE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 13% -8% $195,224,587 25,453,010 0% RA Capital Management, L.P. 11 Dec 2025
Adage Capital Management, L.P. 9.6% +19% $97,607,250 +$16,250,000 15,016,500 +20% Adage Capital Management, L.P. 30 Jun 2025
BlackRock, Inc. 6.1% $57,471,401 9,360,163 BlackRock, Inc. 31 Dec 2024
MAVERICK CAPITAL LTD 5.4% $50,724,026 8,261,242 Maverick Capital, Ltd. 31 Dec 2024
As of 30 Sep 2025, Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share (WVE) has 187 institutional shareholders filing 13F forms. They hold 143,683,496 shares of 189,947,836 outstanding shares (76%) .

Top 25 institutional shareholders own 64% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 9.6% 18,202,009 0% 1.6% $133,238,706
ADAGE CAPITAL PARTNERS GP, L.L.C. 7.7% 14,567,784 -3% 0.17% $106,636,179
BlackRock, Inc. 5.5% 10,430,813 +0.45% 0% $76,353,551
MAVERICK CAPITAL LTD 4.4% 8,391,856 +1.6% 0.82% $61,428,386
Driehaus Capital Management LLC 3.3% 6,298,060 -3.6% 0.33% $46,101,799
M28 Capital Management LP 3% 5,664,548 0% 61% $41,464,491
FMR LLC 2.7% 5,130,374 +729% 0% $37,554,335
Kynam Capital Management, LP 2.4% 4,560,053 0% 2.5% $33,379,588
683 Capital Management, LLC 2.2% 4,150,000 +1.2% 2.8% $30,378,001
Bellevue Group AG 2.2% 4,094,458 0% 0.62% $29,971,433
PRICE T ROWE ASSOCIATES INC /MD/ 2.1% 4,044,492 -22% 0% $29,607,000
FEDERATED HERMES, INC. 2% 3,750,693 +678145% 0.05% $27,455,073
Siren, L.L.C. 1.9% 3,696,322 0% 1.1% $27,057,077
VANGUARD GROUP INC 1.7% 3,139,836 -9.7% 0% $22,983,600
EMERALD ADVISERS, LLC 1.6% 2,996,900 -8% 0.7% $21,937,308
GEODE CAPITAL MANAGEMENT, LLC 1.5% 2,918,370 +5.8% 0% $21,365,183
LOOMIS SAYLES & CO L P 1.5% 2,905,466 -12% 0.03% $21,268,011
STATE STREET CORP 1.5% 2,846,366 +3.3% 0% $20,835,399
GOLDMAN SACHS GROUP INC 1.1% 2,125,137 +111% 0% $15,556,003
STEMPOINT CAPITAL LP 1.1% 2,110,152 +134% 3.1% $15,446,313
Affinity Asset Advisors, LLC 1.1% 2,100,000 +5% 1.4% $15,372,000
PRIMECAP MANAGEMENT CO/CA/ 1% 1,898,650 -23% 0.01% $13,898,118
Pfizer Inc 0.99% 1,875,000 0% 3.1% $13,725,000
EMERALD MUTUAL FUND ADVISERS TRUST 0.93% 1,766,062 -8.8% 0.67% $12,927,574
MPM BIOIMPACT LLC 0.79% 1,505,262 0% 1.8% $11,018,518

Institutional Holders of Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share (WVE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 68,189 $1,159,686 +$1,138,396 $17.00 4
2025 Q3 143,683,496 $1,051,664,882 +$37,209,381 $7.32 187
2025 Q2 138,939,054 $903,136,388 +$46,387,739 $6.50 174
2025 Q1 131,293,097 $1,061,209,500 +$20,316,386 $8.08 192
2024 Q4 128,600,738 $1,590,819,737 +$87,821,907 $12.37 180
2024 Q3 120,131,680 $985,159,356 +$175,012,354 $8.20 159
2024 Q2 93,731,221 $467,718,963 +$9,889,040 $4.99 142
2024 Q1 92,759,614 $572,308,125 -$444,057 $6.17 132
2023 Q4 1,371,684 $7,694,829 -$132,177 $5.34 2
2023 Q3 72,598,087 $417,436,571 +$2,964,681 $5.75 85
2023 Q2 72,146,788 $262,613,298 +$6,600,493 $3.64 79
2023 Q1 70,086,593 $303,466,627 +$3,707,268 $4.33 72
2022 Q4 68,108,089 $476,736,473 +$7,474,869 $7.00 74
2022 Q3 67,126,427 $242,328,542 -$1,791,919 $3.61 56
2022 Q2 67,700,535 $220,025,785 +$70,128,486 $3.25 55
2022 Q1 44,505,507 $89,003,268 -$637,458 $2.00 75
2021 Q4 47,273,566 $148,445,513 +$13,327,878 $3.14 85
2021 Q3 37,428,616 $183,549,240 +$443,920 $4.90 84
2021 Q2 37,041,724 $246,690,021 -$5,824,673 $6.66 83
2021 Q1 38,279,773 $214,770,368 +$1,494,885 $5.61 98
2020 Q4 36,082,417 $283,967,815 -$9,576,389 $7.87 101
2020 Q3 37,117,432 $315,925,313 +$59,250,570 $8.49 105
2020 Q2 29,421,942 $306,284,769 -$6,700,795 $10.41 88
2020 Q1 30,100,828 $282,072,986 +$9,436,808 $9.37 76
2019 Q4 29,216,613 $234,164,963 -$45,093,382 $8.01 85
2019 Q3 30,879,604 $633,952,522 +$1,149,678 $20.53 86
2019 Q2 30,198,680 $787,916,581 +$41,352,230 $26.09 98
2019 Q1 29,379,379 $1,141,323,791 +$192,385,644 $38.85 108
2018 Q4 24,392,678 $1,025,469,934 +$23,046,207 $42.04 90
2018 Q3 23,803,148 $1,190,156,500 -$29,664,597 $50.00 92
2018 Q2 24,464,983 $935,783,108 +$30,294,355 $38.25 76
2018 Q1 23,663,816 $948,860,012 +$61,087,968 $40.10 79
2017 Q4 22,225,342 $780,113,100 +$59,933,410 $35.10 72
2017 Q3 20,492,602 $445,796,252 +$25,433,832 $21.75 58
2017 Q2 19,316,233 $359,305,882 +$66,135,739 $18.60 55
2017 Q1 15,709,867 $431,755,770 +$32,768,294 $27.50 49
2016 Q4 14,817,269 $388,165,611 +$18,110,176 $26.15 50
2016 Q3 14,060,800 $456,548,375 -$3,399,843 $32.47 44
2016 Q2 14,199,612 $293,778,139 +$6,802,346 $20.69 37
2016 Q1 14,000,592 $192,282,000 +$2,926,207 $13.88 22
2015 Q4 13,788,757 $218,725,000 +$83,161,042 $15.95 17